BridgeBio Pharma, Inc.
$84.12 +$0.10 (+0.12%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 24
Offering paper hit the record (Form S-3).
S-3ASR - BridgeBio Pharma, Inc. (0001743881) (Filer)
RECEIPT: SEC FORM S-3, TIMESTAMPED -
Jul 22
A material event was filed (Form 8-K).
8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jul 9
The stock moved +15.1% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 9 -
Feb 5
The stock moved -15.2% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 5
The story updates itself as events post · The wolf reports; you decide
Snapshot
About BridgeBio Pharma, Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.